MichaelSingerMD

Ophthalmology • San Antonio, TX

Retinal Disease

Physician

Join to view full profile

Dr. Singer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Singer's full profile

Already have an account?

Office
9157 Huebner Rd
San Antonio, TX 78240
Phone+1 210-697-2020

Fax+1 210-558-7687

Education & Training

New York Medical College at St Vincent's Hospital and Medical Center of New YorkResidency, Ophthalmology, 1988 - 1991
University of Southern California/LACUSC Medical CenterInternship, Transitional Year, 1986 - 1987
Boston University School of MedicineClass of 1986

Certifications & Licensure

CA State Medical License 1987 - 2027
AZ State Medical License 2003 - 2026
FL State Medical License 1995 - 2026
NV State Medical License 2024 - 2025
TX State Medical License 1995 - 2025
CO State Medical License 1988 - 1993
GA State Medical License 1991 - 1993
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Medflow EHR, Medflow, Inc., 2012-2013
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) Start of enrollment: 2010 Jun 01
Completed
Phase 2, Phase 3
ObseRvation of PeripHEral rEtinal Morphology in Normals Start of enrollment: 2017 Mar 01
Unknown status
TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO) Start of enrollment: 2017 Apr 01
Completed
Phase 2
An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity Start of enrollment: 2022 Jul 01
Recruiting
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

285 citations
HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Michael A Singer, Carl C. Awh, Srinivas R. Sadda, William R. Freeman, Andrew N. Antoszyk
Ophthalmology. 2012-06-01
1370 citations
Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep Learning
Daniel S. Kermany, Michael H. Goldbaum, Wenjia Cai, Carolina C. S. Valentim, Huiying Liang
Cell. 2018-02-22
44 citations
The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results.
Arshad M Khanani, Aamir A Aziz, Hannah Khan, Ashwin Gupta, Ohidul Mojumder
Eye. 2023-12-01

Press Mentions

RWC Update: Dislocated DSEK Flap; Ellipsoid Zone as a Surrogate Efficacy Endpoint in Clinical Trials; Retinal Tear Associated with Lattice DegenerationAugust 1st, 2024
Nanoscope Therapeutics' Optogenetic Gene Therapy to Be Featured in Presentation at Stanford University's Innovate Retina Summit Dec. 11, 2021December 8th, 2021
Nanoscope Therapeutics Announces New Clinical Advisory Board AppointmentsApril 19th, 2021
Join now to see all

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow